Tessera Therapeutics, a company developing a genetic approach to treat and prevent diseases with backing from Flagship Pioneering, raised more than $300 million in its latest round.
Tessera is experimenting with a technology called gene writing to fight cancer, cystic fibrosis, sickle cell disease and multiple liver diseases, Chief Executive Officer Geoffrey von Maltzahn said. The funding “is about getting us into the clinic,” he said in an interview, without giving specifics on when human trials might begin.
